Hydrochlorothiazide

Hydrochlorothiazide (CAS 58-93-5), commonly abbreviated as HCTZ, is a thiazide diuretic active pharmaceutical ingredient used in the treatment of hypertension and edema.

It is one of the most established antihypertensive APIs in global pharmaceutical manufacturing, appearing in both standalone formulations and fixed-dose combinations.

HCTZ is a primary active ingredient in oral solid dosage forms, such as tablets and capsules, targeting cardiovascular and renal indications for patients worldwide.

Fixed-dose combination products pairing HCTZ with ACE inhibitors, ARBs, or beta-blockers represent a major share of its commercial demand in the pharmaceutical sector.

Generic pharmaceutical manufacturers source it as a finished API for direct compression or wet granulation processes to ensure efficient production cycles.

Contract formulators also use it as a reference standard component in bioequivalence and analytical method development for various regulatory submission requirements.

Hydrochlorothiazide is supplied as a white to off-white crystalline powder. It is available in USP, BP, and Ph. Eur. compendial grades to meet global standards.

Micronized grades are available where particle size control is critical to dissolution performance and content uniformity in finished dosage forms for high-quality manufacturing.